Source:http://linkedlifedata.com/resource/pubmed/id/17145229
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2006-12-5
|
pubmed:abstractText |
The aim of this study was to investigate the time course of C-reactive protein (CRP) reduction with simvastatin in patients with type 2 diabetes mellitus. Thirty-five subjects (mean +/- SEM body mass index 32.8 +/- 1 kg/m(2), mean +/- SEM glycated hemoglobin 7.3 +/- 0.2%) were studied using a randomized, crossover, double-blind design. Patients were treated with simvastatin 40 mg or placebo for 28 days, with a minimum 28-day intervening washout. On entry, all subjects had low-density lipoprotein cholesterol >100 mg/dl and/or non-high-density lipoprotein cholesterol >130 mg/dl. High-sensitivity CRP (hs-CRP) was measured on days 0, 1, 3, 7, 14, 21, and 28 of each phase; fasting lipids were measured weekly. The mean hs-CRP level was 4.2 +/- 0.6 mg/L at baseline (>3.0 mg/L represents high risk). After simvastatin administration, there was a significant reduction in levels of log(hs-CRP) (p = 0.001). This effect of simvastatin was seen by day 7 (p = 0.008), with maximal reduction seen at day 14 (p = 0.004; hs-CRP in original units 3.1 +/- 0.5 mg/L with simvastatin and 4.1 +/- 0.6 mg/L with placebo). As expected, the change in hs-CRP was not related to low-density lipoprotein cholesterol reduction. By day 28 with simvastatin, hs-CRP had returned to near baseline levels. In conclusion, in patients with type 2 diabetes mellitus, simvastatin reduced hs-CRP within 7 days. However, this potentially beneficial effect was lost within 28 days.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Simvastatin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0002-9149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
98
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1656-9
|
pubmed:dateRevised |
2007-12-3
|
pubmed:meshHeading |
pubmed-meshheading:17145229-Adult,
pubmed-meshheading:17145229-Aged,
pubmed-meshheading:17145229-Anticholesteremic Agents,
pubmed-meshheading:17145229-C-Reactive Protein,
pubmed-meshheading:17145229-Cholesterol, LDL,
pubmed-meshheading:17145229-Cross-Over Studies,
pubmed-meshheading:17145229-Diabetes Mellitus, Type 2,
pubmed-meshheading:17145229-Double-Blind Method,
pubmed-meshheading:17145229-Dyslipidemias,
pubmed-meshheading:17145229-Female,
pubmed-meshheading:17145229-Humans,
pubmed-meshheading:17145229-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:17145229-Male,
pubmed-meshheading:17145229-Middle Aged,
pubmed-meshheading:17145229-Simvastatin
|
pubmed:year |
2006
|
pubmed:articleTitle |
Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
|
pubmed:affiliation |
Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver & Health Sciences Center, Denver, CO, USA. teri.hernandez@uchsc.edu
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|